BG-45

• CAT Number: I005513
• CAS Number: 926259-99-6
• Molecular Formula: C₁₁H₁₀N₄O
• Molecular Weight: 214.23
• Purity: ≥95%
• Synonyms: BG-45
• Target: HDAC
• Solubility: DMSO: ≥ 48 mg/mL
• Storage: 2-8°C
• IC50: 289 nM (HDAC3), 2 μM (HDAC1), 2.2 μM (HDAC2), >20 μM (HDAC6)
• IUPAC Name: N-(2-aminophenyl)pyrazine-2-carboxamide
• InChI: InChI=1S/C11H10N4O/c12-8-3-1-2-4-9(8)15-11(16)10-7-13-5-6-14-10/h1-7H,12H2,(H,15,16)
• InChIKey: LMWPVSNHKACEKW-UHFFFAOYSA-N
• SMILES: C1=CC=C(C(=C1)N)NC(=O)C2=NC=CN=C2

BG-45（Cat No.:I005513）is a small-molecule inhibitor that selectively targets bromodomain and extraterminal domain (BET) proteins, particularly BRD4. By disrupting the interaction between BRD4 and acetylated histones, BG-45 inhibits transcription of oncogenes associated with cancer progression. This compound has shown potential in preclinical studies for treating various malignancies, including leukemia and solid tumors, by enhancing the efficacy of conventional therapies. BG-45’s ability to modulate gene expression and influence cell cycle dynamics makes it a promising candidate in cancer research, aimed at improving therapeutic outcomes in resistant cancers.

Reference

[1]. Iaconelli J, et al. HDAC6 Inhibitors Modulate Lys49 Acetylation and Membrane Localization of β-Catenin in Human iPSC-Derived Neuronal Cells. ACS Chemical Biology (2015), 10(3), 883-890.